Inozyme Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Inozyme Pharma, Inc. (Nasdaq: INZY), a biopharmaceutical company focused on therapies for abnormal mineralization, announced that CEO Axel Bolte will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 7:00 AM ET. The presentation will be available on-demand and can be accessed through Inozyme's Investor Relations page for a limited time. The company is developing INZ-701, a novel therapy currently in Phase 1/2 trials to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases impacting mineralization pathways.

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference. The prerecorded presentation will become available on-demand on Monday, September 12, 2022, at 7:00 AM ET.

A replay of the presentation can be accessed from the Investor Relations section of Inozyme’s website and will be available for a limited time following the event.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com.

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
(857) 330-8871
stefan.riley@inozyme.com        

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

 

FAQ

When will Inozyme Pharma's CEO present at the Global Investment Conference?

Axel Bolte, CEO of Inozyme Pharma, will present on September 12, 2022, at 7:00 AM ET.

How can I access the presentation from Inozyme Pharma's CEO?

The presentation can be accessed on-demand through the Investor Relations section of Inozyme's website after September 12, 2022.

What is INZ-701 being developed for by Inozyme Pharma?

INZ-701 is being developed for the treatment of ENPP1 and ABCC6 Deficiencies, which are rare genetic diseases.

What stage of clinical trials is INZ-701 currently in?

INZ-701 is currently in Phase 1/2 clinical trials.

What is Inozyme Pharma's focus in biopharmaceuticals?

Inozyme Pharma focuses on developing therapeutics for diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeleton.